Impact of clinical and demographic characteristics on patient preferences for psoriasis treatment features: Results from a discrete-choice experiment in a multicountry study

References

• Pariser DM, Bagel J, Gelfand JM, et al. National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol. 2007;143(2):239–242.
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DP, Griffiths CE, et al. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
   PubMed Web of Science ®Google Scholar
• Danielsen K, Olsen AO, Wilsgaard T, et al. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol. 2013;68(6):1303–1310.
   Web of Science ®Google Scholar
• WHO. 2016. Global report on psoriasis. [Accessed 23 September 2019]. http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf
   Google Scholar
• Umar N, Yamamoto S, Loerbroks A, et al. Elicitation and use of patients’ preferences in the treatment of psoriasis: a systematic review. Acta Derm Venereol. 2012;92:339–409.
   Web of Science ®Google Scholar
• Gonzalez JM. Evaluating risk tolerance from a systematic review of preferences: the case of patients with psoriasis. Patient. 2018;11(3):285–300.
   PubMedGoogle Scholar
• Ashcroft DM, Seston E, Griffiths CE. Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists. Br J Dermatol. 2006;155(6):1236–1241.
   PubMed Web of Science ®Google Scholar
• Seston EM, Ashcroft DM, Griffiths CE. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. Arch Dermatol. 2007;143(9):1175–1179.
   PubMedGoogle Scholar
• Schaarschmidt ML, Schmieder A, Umar N, et al. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol. 2011;147(11):1285–1294.
   PubMedGoogle Scholar
• Hauber AB, Gonzalez JM, Schenkel B, et al. The value to patients of reducing lesion severity in plaque psoriasis. J Dermatolog Treat. 2011;22(5):266–275.
   PubMed Web of Science ®Google Scholar
• Schmieder A, Schaarschmidt ML, Umar N, et al. Comorbidities significantly impact patients' preferences for psoriasis treatments. J Am Acad Dermatol. 2012;67(3):363–372.
   PubMed Web of Science ®Google Scholar
• Schaarschmidt ML, Umar N, Schmieder A, et al. Patient preferences for psoriasis treatments: impact of treatment experience. J Eur Acad Dermatol Venereol. 2013;27(2):187–198.
   PubMed Web of Science ®Google Scholar
• Torbica A, Fattore G, Ayala F. Eliciting preferences to inform patient-centred policies: the case of psoriasis. Pharmacoeconomics. 2014;32(2):209–223.
   PubMed Web of Science ®Google Scholar
• Kromer C, Schaarschmidt ML, Schmieder A, et al. Patient preferences for treatment of psoriasis with biologicals: a discrete choice experiment. PLoS One. 2015;10(6):e0129120.
   PubMed Web of Science ®Google Scholar
• Kauf T, Yang JC, Kimball AB, et al. Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy. J Dermatolog Treat. 2015;26(6):507–513.
   PubMed Web of Science ®Google Scholar
• Schaarschmidt M-L, Kromer C, Herr R, et al. Patient preferences for biologicals in psoriasis: top priority of safety for cardiovascular patients. PLoS One. 2015;10(12):e0144335.
   PubMed Web of Science ®Google Scholar
• Feldman S, Moeller A, Idemyr S. Relative importance of mode of administration in treatment preferences among plaque psoriasis patients in the United States. JHEOR. 2016;4(2):141–157.
   Google Scholar
• Rothery C, Bojke L, Richardson G, et al. A discrete choice experiment to explore patients' willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis. Clin Rheumatol. 2016;35(12):2967–2974.
   PubMed Web of Science ®Google Scholar
• Kromer C, Peitsch WK, Herr R, et al. Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability. J Dtsch Dermatol Ges. 2017;15(2):189–200.
   Web of Science ®Google Scholar
• Eliasson L, Bewley AP, Mughal F, et al. Evaluation of psoriasis patients' attitudes toward benefit-risk and therapeutic trade-offs in their choice of treatments. Patient Prefer Adherence. 2017;11:353–362.
   PubMed Web of Science ®Google Scholar
• Gonzalez JM, Johnson FR, McAteer H, et al. Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the UK: results from a discrete-choice experiment. Br J Dermatol. 2017;176(3):777–785.
   PubMed Web of Science ®Google Scholar
• Fairchild AO, Reed SD, Johnson FR, et al. What is clearance worth? Patients' stated risk tolerance for psoriasis treatments. J Dermatolog Treat. 2017;28(8):709–715.
   PubMed Web of Science ®Google Scholar
• Schaarschmidt ML, Herr R, Gutknecht M, et al. Patients' and physicians' preferences for systemic psoriasis treatments: a nationwide comparative discrete choice experiment (PsoCompare). Acta Derm Venereol. 2018;98(2):200–205.
   PubMed Web of Science ®Google Scholar
• Boeri M, Saure D, Schacht A, et al. Modeling heterogeneity in patients' preferences for psoriasis treatments in a multicountry study: a comparison between random-parameters logit and latent class approaches. Pharmacoeconomics. 2020;38(6):593–606.
   PubMed Web of Science ®Google Scholar
• Christophers E, Griffiths CE, Gaitanis G, et al. The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review. J Eur Acad Dermatol Venereol. 2006; Sep20(8):921–925.
   PubMed Web of Science ®Google Scholar
• Torres T, Hammadi AA, Elgendi AM, et al. Access to information on psoriasis treatment and disease: Which different sources do patients use? Results from an international survey. 24th World Congress of Dermatology. 2019. Milan, Italy.
   Google Scholar
• Zaheri S, Chen KS, McKenzie R, et al. Greater communication between UK psoriasis patients and their dermatologists may improve treatment satisfaction: results from an international psoriasis survey. 99th Annual Meeting of the British Association of Dermatologists. 2019. Liverpool, United Kingdom.
   Google Scholar
• Ribera M, Herranz P, Huete T, et al. Patient expectations and satisfaction with psoriasis treatment in Spain: results from an international patient survey. 47th National Congress of the Spanish Academy of Dermatology and Venereology (AEDV). 2019. Barcelona, Spain.
   Google Scholar
• Barker J, McKenzie R, Saure D, et al. Patient expectations and satisfaction in psoriasis treatment: a survey from Europe and Canada. 5th World Psoriasis & Psoriatic Arthritis Conference (IFPA). 2018. Stockholm, Sweden.
   Google Scholar
• Reich A, Esposito M, Wilhelm S, et al. Unmet needs in the patient-physician communication in psoriasis: results from an international, quantitative survey. 15th European Academy of Dermatology and Venereology (EADV) Spring Symposium. 2018. Budva, Montenegro.
   Google Scholar
• Viguier M, Saure D, Dossenbach M, et al. The impact of psoriasis on quality of life in Europe and Canada. 82nd AAD Annual Meeting. 2018. San Diego, California.
   Google Scholar
• Sawtooth Software, Inc. CBC User Manual. Sequim: Sawtooth Software; 1999.
   Google Scholar
• Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CGM, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016; 19(4):300–315.
   PubMed Web of Science ®Google Scholar
• Greene WH. 2012 Econometric analysis. 7th ed. Boston: Pearson.
   Google Scholar